Niktimvo-Axatilimab-Csfr
Niktimvo is an IV antibody treatment for adults and children (≥ 40 kg) with chronic graft‑versus‑host disease whose condition worsened despite at least two prior therapies. It works by blocking CSF‑1R to calm overactive immune cells and reduce symptoms.
Ebglyss-Lebrikizumab-Lbkz
Ebglyss is used to treat moderate-to-severe atopic dermatitis. It addresses the inflammation caused by eczema all over your body, resulting in persistently dry, itchy, and irritated skin.
Hympavzi-Marstacimab-Hncq
Hympavzi is a subcutaneous antibody given to patients aged 12 and older to prevent bleeding episodes in hemophilia A or B without factor inhibitors. It works by inhibiting the tissue factor pathway to reduce the frequency of bleeds.
Nemluvio-Nemolizumab-Ilto
Nemluvio is an injectable antibody for adults suffering from debilitating itch in prurigo nodularis or moderate-to-severe atopic dermatitis. It blocks the IL‑31 receptor to reduce itching and improve skin healing, offering relief within 48 hours.
Anktiva-Nogapendekin Alfa Inbakicept-Pmln
Anktiva is the first FDA-approved immunotherapy that activates the immune system to treat BCG-unresponsive non-muscle invasive bladder cancer (CIS), offering some patients a lasting complete response.
Imdelltra-Tarlatamab-Dlle
Imdelltra is used to treat adults with extensive-stage small cell lung cancer (ES-SCLC) that has returned after platinum-based chemotherapy.
Kisunla-Donanemab-Azbt
Kisunla is used to treat Alzheimer’s disease. It is an FDA-approved treatment for early symptomatic Alzheimer’s disease, including mild cognitive impairment and the mild dementia stage of the condition.
Alhemo-Concizumab-Mtci
Alhemo is a preventive injection for people with hemophilia A or B with inhibitors, aged 12 and above. It helps reduce and prevent bleeding episodes by regulating the clotting pathway.
Piasky-Crovalimab-Akkz
Nemluvio is an injectable antibody for adults suffering from debilitating itch in prurigo nodularis or moderate-to-severe atopic dermatitis. It blocks the IL‑31 receptor to reduce itching and improve skin healing, offering relief within 48 hours.
Datroway-Datopotamab Deruxtecan-Dlnk
Datroway is an antibody-drug conjugate for adults with advanced non-small cell lung cancer that has an EGFR mutation and progressed after standard treatment. It delivers targeted chemotherapy directly to cancer cells to control tumor growth.
